Skip to main content

Table 1 Clinical features of CML patients.

From: Influence of cytochrome P450 and glutathione S transferase polymorphisms on response to nilotinib therapy among chronic myeloidleukemia patients from Pakistan

Clinical Parameters

Numberā€‰=ā€‰99

Sokal relative risk score

ā€ƒ<ā€‰0.8

66

ā€ƒ0.8ā€“1.2

27

ā€ƒ>ā€‰1.2

6

Phase at diagnosis

ā€ƒChronic

97

ā€ƒAccelerated

2

ā€ƒBlast Crisis

0

Treatment Outcome

ā€ƒResponders

66

ā€ƒPartial Responders

21

ā€ƒNon-Responders

12

Hematological Response

ā€ƒComplete

66

ā€ƒPartial

30

ā€ƒNo

3

Molecular Response

ā€ƒMajor MolecularResponse

21

ā€ƒDeep MolecularResponse

45

ā€ƒNo Molecular Response

33

Progression

ā€ƒYes

10

ā€ƒNo

89

Status

ā€ƒAlive

93

ā€ƒDead

6